Can organs be separated at Wellness Clinics America?
A kidney result can count cardiovascular deaths. A liver improvement can depend on what happens to another tissue feature. Wellness becomes harder to divide into departments.
Organ outcomes overlap
Adults in STEP 5
The STEP 5 semaglutide trial reported sustained mean weight reduction over 104 weeks, significantly greater than placebo, in adults with overweight or obesity. A body-weight result concerns the body as a whole. The organ headings that follow seem tidier, until their outcomes begin crossing those divisions.
I admire the time spent on the question. A result followed for two years has a different interest from the excitement around an early change, although an average still leaves individual experiences out of sight. The persistence of the result is impressive. The clinical findings that a weight measurement cannot describe deserve just as much attention.
The earlier STEP 1 trial enrolled 1,961 adults with overweight or obesity without diabetes. Mean body-weight change from baseline to week 68 was -14.9% with semaglutide and -2.4% with placebo. Those are substantial findings about the people studied. Wellness, as an ambition, asks how those organ results connect. A collection of favourable findings cannot establish that every part of the body improved together.
Where organ outcomes overlap
The primary kidney composite in FLOW included kidney failure, at least a 50% decline in eGFR, or death from kidney or cardiovascular causes. A cardiovascular death can therefore contribute to what is reported as a kidney outcome. That detail disrupts the neat division into organs that I expected from the trial’s subject.
The ESSENCE liver trial required biopsy-confirmed MASH with stage 2-3 fibrosis. Its tissue endpoints paired resolution of steatohepatitis with no worsening fibrosis, and fibrosis improvement with no worsening steatohepatitis. Even inside one organ, improvement has a neighbouring feature to answer to. I enjoy how these reports complicate wellness through overlapping consequences, even before any attempt to give each organ a score.
The study rooms
Heart outcomes brings together cardiovascular events, an eye-complication finding and the symptoms of a specific form of heart failure. The eye finding reaches beyond the organ in the page’s name.
Kidney disease concentrates on FLOW and the cardiovascular component within its kidney composite. Liver biopsies moves into tissue, where resolution of steatohepatitis without worsening fibrosis and fibrosis improvement without worsening steatohepatitis receive separate tests.
Alcohol use disorder has a much smaller human trial and an unusually concrete laboratory task. It deserves its own room, away from the weight-loss results that could otherwise overwhelm it. That page also marks a limit: a separate trial does not establish how drinking, weight and organ outcomes change together.
Tolerability
Treatment difficulties also cross the tidy organ headings. The dedicated safety review describes predominantly mild-to-moderate, transient gastrointestinal effects and an increased risk of biliary disease, while judging the overall risk-benefit profile favourably in type 2 diabetes. That favourable judgement retains both its type 2 diabetes setting and its cautions.
The cardiovascular page considers an especially awkward pairing: a beneficial cardiovascular result alongside more diabetic-retinopathy complications in SUSTAIN-6. I think a broad account of wellness has to make room for that discomfort.